Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial.

Jan Paweł BembenekMaciej NiewadaBożena KłyszAnna MazurKatarzyna KurczychMarcin GłuszkiewiczAnna Członkowska

Published in: Neurologia i neurochirurgia polska (2020)

Consistent with other trials based on the FOCUS protocol, fluoxetine did not improve motor recovery or general stroke outcome at six and 12 months in the Polish cohort studied. However, patients receiving fluoxetine required therapy with additional antidepressant medication less frequently.

Keyphrases

placebo controlled
study protocol
double blind
atrial fibrillation
phase iii
clinical trial
phase ii
randomized controlled trial
open label
major depressive disorder
squamous cell carcinoma
stem cells
bone marrow
adverse drug
mesenchymal stem cells
bipolar disorder